Search results for "farmacologia"

showing 10 items of 411 documents

Design, synthesis and biological evaluation of new anticancer drugs: FGFR inhibitors

2021

Fibroblast growth factor receptors (FGFRs) constitute a family of tyrosine kinases receptors (RTKs) that exert pivotal physiological functions in human embryonic and adult tissues. Hyperactivated FGFR signaling drives tumorigenesis in multiple cancer types, including lung and brain cancers. Great effort has been laid on the development of new compounds that specifically target the FGFR axis. However, cancer cell- based and microenvironmental resistance mechanisms against FGFR inhibitors often arise and are currently poorly understood. Furthermore, FGFR-targeted therapy often presents different side effects, e due to the broad biological spectrum of the FGFR signaling axis as well as to its …

DesignhypoxiabrainglioblastomatransitionAnticancer drugs FGFR Drug design Ubiquitin Brain tumor Glioblastoma Lung cancer NSCLC SCLC Copper complexes Hypoxia activated drugs Metal drugsSettore BIO/11 - Biologia MolecolareSettore CHIM/08 - Chimica Farmaceuticalungmetal complexeFGFR1Settore CHIM/03 - Chimica Generale E InorganicacopperSettore BIO/10 - BiochimicaFGFR4Settore BIO/14 - Farmacologiacancersynthesi
researchProduct

Anti-Inflammatory Activity of Citrus bergamia Derivatives: Where Do We Stand?

2016

Inflammatory diseases affect a large portion of the worldwide population, and chronic inflammation is a major risk factor for several dangerous pathologies. To limit the side effects of both synthetic and biological anti-inflammatory drugs, the use of herbal medicines, nutraceuticals and food supplements has increased tremendously as alternative and/or complementary medicine to treat several pathologies, including inflammation. During the last decades, the biological properties of Citrus bergamia (bergamot) derivatives have obtained important scientific achievements, and it has been suggested their use in a context of a multitarget pharmacological strategy. Here, we present an overview of t…

0301 basic medicineCitrusnatural productsAnti-Inflammatory AgentsCitruantioxidant activityPharmaceutical SciencebergamotReviewPharmacologyAnalytical Chemistry0302 clinical medicinecomplementary and alternative medicinesDrug DiscoveryCitrus bergamiaeducation.field_of_studyTraditional medicineMedicine (all)3. Good healthAnti-Inflammatory AgentChemistry (miscellaneous)030220 oncology & carcinogenesisMolecular MedicineComplementary medicineHumanmedicine.drug_classHerbal MedicinePopulationContext (language use)Natural productAnti-inflammatoryPlant ExtractAntioxidant activity; Bergamot; Citrus bergamia; Complementary and alternative medicines; Flavonoids; Inflammation; Natural products; Anti-Inflammatory Agents; Citrus; Herbal Medicine; Humans; Inflammation; Plant Extracts; Organic Chemistrylcsh:QD241-44103 medical and health sciencesNutraceuticallcsh:Organic chemistrySettore MED/43 - Medicina LegaleBiological propertymedicineHumansPhysical and Theoretical ChemistryeducationAntioxidant activity Bergamot Citrus bergamia Complementary and alternative medicines Flavonoids Inflammation Natural products Medicine (all);Plant Extractsbusiness.industryOrganic Chemistry030104 developmental biologyComplementary and alternative medicineinflammationflavonoidsCitrus bergamiaFlavonoidSettore BIO/14 - FarmacologiabusinessMolecules
researchProduct

REM sleep behavior disorder in a patient with frontotemporal dementia

2010

We describe a patient with frontotemporal dementia (FTD), a tauopathy, who also showed clinical and polysomnographic features of REM sleep behavior disorder (RBD). The patient is a 78-year-old male with a 1 year history of behavioral dysfunction involving emotion, character and social functioning. Brain imaging and the results of neuropsychological testing were consistent with a diagnosis of FTD. Sleep symptom onset occurred some years before the behavioral changes, and consisted of unpleasant dreams, vocalization, and prominent motor behaviors. A polysomnography confirmed the diagnosis of RBD. Our findings support the hypothesis that RBD, although more frequent in synucleinopathies, might …

Malemedicine.medical_specialtyNeurologyREM Sleep Behavior DisorderDermatologyPolysomnographyAudiologySettore BIO/09 - FisiologiaREM sleep behavior disorderMuscle tonemental disordersmedicineHumansPsychiatryAgedSleep disordermedicine.diagnostic_testElectromyographyREM sleep behaviorGeneral MedicineParasomniamedicine.diseaseElectrooculographyPsychiatry and Mental healthmedicine.anatomical_structureFrontotemporal DementiaSettore BIO/14 - FarmacologiaSettore MED/26 - NeurologiaNeurology (clinical)TauopathyPsychologyFrontotemporal dementiaNeurological Sciences
researchProduct

ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker.

2019

Abstract Alzheimer’s disease (AD) represents a global burden in the economics of healthcare systems. Amyloid-β (Aβ) peptides are formed by amyloid-β precursor protein (AβPP) cleavage, which can be processed by two pathways. The cleavage by the α-secretase A Disintegrin And Metalloprotease 10 (ADAM10) releases the soluble portion (sAβPPα) and prevents senile plaques. This pathway remains largely unknown and ignored, mainly regarding pharmacological approaches that may act via different signaling cascades and thus stimulate non-amyloidogenic cleavage through ADAM10. This review emphasizes the effects of natural compounds on ADAM10 modulation, which eventuates in a neuroprotective mechanism. M…

0301 basic medicineFarmacologiaADAM10DiseaseRM1-950Natural compoundsCleavage (embryo)NeuroprotectionCatechin03 medical and health sciencesADAM10 ProteinAmyloid beta-Protein Precursor0302 clinical medicineAlzheimer DiseaseDisintegrinHumansSenile plaquesPharmacological modulationPharmacologyMetalloproteinaseAmyloid beta-PeptidesbiologyChemistryPlant ExtractsADAM10ProteinsGinkgo bilobaMembrane ProteinsGeneral Medicineα-SecretaseAlzheimer's disease030104 developmental biologyMalaltia d'AlzheimerNeuroprotective Agents030220 oncology & carcinogenesisPharmaceuticalbiology.proteinTherapeutics. PharmacologyAmyloid Precursor Protein SecretasesNeuroscienceAlzheimer’s diseaseProteïnesBiomarkersBiomedicinepharmacotherapy = Biomedecinepharmacotherapie
researchProduct

Rilevanza clinica delle interazioni farmacologiche di tipo farmacocinetico [Clinical significance of pharmacokinetic interactions]

2008

The correct realization of a pharmacological therapy needs the individuation of the most appropriate drugs for the treatment of the patient's disease. However, even the most effective, and potent and appropriate drugs cannot assure the therapeutic success, if that compound does not reach the site of action. This result can be obtained only if the physician knows the factors that regulate thepharmacokinetic parameters of the used drugs, i.e. absorption, distribution, metabolism, excretion, that regulate the onset velocity, the duration and the intensity of the drug effects. In the lost years, pharmacological interactions, i.e. the possibility that co-administered drugs interfere with each ot…

Clinical significance Pharmacokinetics Pharmacological interactionsSettore BIO/14 - Farmacologia
researchProduct

Hepatotoxicity caused by mebendazole in a patient with Gilbert's syndrome

2019

What is known and objective Mebendazole (MBZ) is a broad-spectrum antihelminthic agent of the benzimidazole type. Although MBZ has been reported to cause hepatic injury, case reports of severe hepatic injury are very rare. We report a case of severe hepatitis after administration of MBZ in a patient with Gilbert's syndrome affected by pinworms infestation. Case summary Differently from other cases of hepatitis due to MBZ reported in the scientific literature, our patient received standard doses of MBZ for a short period of time. After 18 days from the start of therapy, he developed hepatomegaly, and increases in hepatic enzymes and bilirubin. Hepatic enzymes returned to normal over the foll…

medicine.medical_specialtyGlucuronosyltransferaseSettore MED/17 - Malattie InfettiveBilirubinMebendazoleGlucuronidation030226 pharmacology & pharmacyGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineMedicinePharmacology (medical)030212 general & internal medicinePharmacologyHepatitisLiver injurybiologybusiness.industrydrug toxicity Gilbert's syndrome hepatitis mebendazolemedicine.diseaseAntihelminthic AgentGilbert's syndromechemistrySettore BIO/14 - Farmacologiabiology.proteinbusinessmedicine.drugJournal of Clinical Pharmacy and Therapeutics
researchProduct

Exposure to ototoxic agents and hearing loss: A review of current knowledge

2014

Several experimental and clinical studies have shown that a variety of ototoxic agents (such as drugs, industrial chemicals and noise) can cause sensorineural hearing loss. The most common ototoxic drugs used in clinical practice include: aminoglycoside and macrolide antibiotics, quinoline anti-malarials, platinum analog antineoplastics, loop diuretics, and acetylsalicylic acid. Among chemical agents with potential ototoxic properties are: organic solvents, heavy metals, organotins, nitriles, asphyxiants, and pesticides/herbicides. Acoustic exposure to high intensity and/or prolonged noise can also cause permanent threshold shifts in auditory perception. Ototoxic agents can influence audito…

medicine.medical_specialtypharmacological injuryEndolymphHearing lossototoxicity hearing loss pharmacological injury reactive oxygen speciesPharmacologyAudiologyProinflammatory cytokineSpeech and HearingAtrophyOtotoxicitymedicinehearing lossreactive oxygen specieschemistry.chemical_classificationReactive oxygen speciesbusiness.industrySettore MED/44 - Medicina Del LavoroAminoglycosidemedicine.diseaseototoxicity; hearing loss; pharmacological injury; reactive oxygen speciesSettore MED/32 - AudiologiaototoxicitySettore MED/31 - Otorinolaringoiatriamedicine.anatomical_structureOtorhinolaryngologychemistrySettore BIO/14 - FarmacologiaSensorineural hearing lossmedicine.symptombusinessHearing, Balance and Communication
researchProduct

METHADONE VERSUS BUPRENORPHINE: DATA DETECTED FROM CALTANISSETTA SER.T

2018

In last years, heroin-addicted have exponentially increased: this has made it necessary to identify a pharmacological strategy as effective as possible. With this purpose, a statistical investigation was conducted in a sample of individuals, aged between 18 and 50. They were diagnosed and subjected to different treatments at Ser.T of Caltanissetta (Sicily-Italy) during the period 2013-2017. The analyzed patients were treated with three different pharmacological therapy: methadone 0.1%, methadone 0.5%, buprenorphine and suboxone. We obtained percentages of RESPONDERS, LOW RESPONDERS and NON RESPONDERS patients from data processing, based on used therapy. Considering pharmacological responses…

methadonesuboxoneSettore BIO/14 - Farmacologiabuprenorphine
researchProduct

Alteration of the YY1/RKIP ratio is a frequent event in hepatocellular carcinoma

2009

Yin Yang 1 Raf-1 kinase inhibitor protein Hepatocellular carcinoma ApoptosisSettore MED/12 - GastroenterologiaSettore MED/06 - Oncologia MedicaSettore BIO/14 - Farmacologia
researchProduct

RICOVERI PER EFFETTI INDESIDERATI DA SOVRADOSAGGIO DI FARMACI PRESSO UN’UNITÀ OPERATIVA CARDIOLOGICA NEL PERIODO 2011-2013

2014

Introduzione: Le statistiche dei casi di ricovero ospedaliero per effetti indesiderati da sovradosaggio farmacologico sono utili per valutare l’incidenza di tale fenomeno nel mondo reale. Un sovradosaggio farmacologico può avvenire come conseguenza di un’insufficiente o inadeguata comunicazione tra medico e paziente, per autoprescrizione o erronea assunzione di dosaggi superiori a quelli necessari, per erronea assunzione di due farmaci identici come molecola ma con nome commerciale diverso o per effetti collaterali imprevisti. Materiali e metodi: Sono state esaminate, retrospettivamente, le cartelle cliniche relative a tutti i ricoveri avvenuti presso l’Unità Operativa di Cardiologia del P.…

Settore BIO/14 - FarmacologiaSovradosaggio Farmaci Digossina Amiodarone
researchProduct